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The hippocampus is believed to play a crucial role in seizure generation in temporal lobe 
epilepsy (TLE), a common form of medication-resistant epilepsy. This preclinical study 
evaluated chemogenetics as a potential therapy for TLE. Using this approach, excitatory 
neurons of the epileptic hippocampus were selectively inhibited through ligand-based 
activation of an inhibitory Designer Receptor Exclusively Activated by Designer Drugs 
(DREADD).  
The intraperitoneal kainic acid rat model for TLE was used. Animals (n=6) were injected in 
right hippocampus with adeno-associated viral vector carrying CamKIIα-hM4Di-mCherry. Two 
weeks after injection, rats were bilaterally implanted with depth electrodes in the dentate gyrus 
and CA1 region of both hippocampi. Seizure frequency before and after activating DREADDs 
with subclinical doses of clozapine was determined using continuous video-EEG recordings. 
First, EEG was monitored during a baseline period of six days. Next, single injections of 
different clozapine doses (0.01, 0.1 or 1 mg/kg bodyweight/24h, s.c.) and vehicle were 
compared. For each dose, EEG was monitored during three days of treatment. Finally, one 
dose was selected to evaluate an improved dosing scheme in a randomized-blind trial. EEG 
was monitored during a baseline period of one days, followed by one day of treatment with 
clozapine (0.1mg/kg bodyweight/6h) or vehicle. In all experiments, seizure frequency during 
baseline recordings was used to normalize the data.  
Clozapine-induced activation of DREADDs had a dose-dependent seizure suppressing effect.  
Clozapine doses of 0.01, 0.1 and 1 mg/kg resulted in a clear lag in average cumulative seizure 
frequency of about 2, 5 and 8 hours respectively. Repeated clozapine administration resulted 
in a strong suppression of epileptic seizures in all animals tested. During treatment, the 
average daily seizure frequency was reduced with 86%±7% (SEM).  
Clozapine-mediated activation of hM4Di DREADDs in excitatory hippocampal neurons 
temporary suppresses spontaneous seizures in a rat model for TLE in a dose-dependent way. 
Repeated clozapine administration results in a sustained suppression of epileptic seizures. 
